Focused On-demand Library for C-type lectin domain family 4 member A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UMR7

UPID:

CLC4A_HUMAN

Alternative names:

C-type lectin DDB27; C-type lectin superfamily member 6; Dendritic cell immunoreceptor; Lectin-like immunoreceptor

Alternative UPACC:

Q9UMR7; Q17R69; Q8WXW9; Q9H2Z9; Q9NS33; Q9UI34

Background:

C-type lectin domain family 4 member A, also known as Dendritic cell immunoreceptor, plays a pivotal role in immune regulation. It binds specific carbohydrates, such as mannose and fucose, in a calcium-dependent manner, facilitating antigen internalization and presentation. This process is crucial for the activation of CD8(+) T cells, enhancing immune responses against pathogens. Additionally, it interacts with HIV-1, influencing virus binding and infection.

Therapeutic significance:

Understanding the role of C-type lectin domain family 4 member A could open doors to potential therapeutic strategies. Its involvement in antigen presentation and immune response modulation presents a unique opportunity for developing treatments aimed at enhancing immune defense mechanisms, particularly in viral infections such as HIV.